Table 30:
Volume of Thrombolytic Infusion With Mechanical Thrombectomy Use in Acute and Subacute DVT in Observational Studies
| Results | ||||
|---|---|---|---|---|
| Author, year | Outcome measurementa | MT | Comparator | P value |
| PMT (AngioJet) | ||||
| Huang et al, 202197 | Mean urokinase dosing postoperatively | 5.22 (SD ± 3.49) | 24.97 (SD ± 4.60) | P = .000 |
| Kuo et al, 201798 | Mean urokinase dose | 179.33 (SD ± 23.1) | 276.35 (SD ± 67.8) | P < .001 |
| Lee et al, 202099 | Mean total urokinase | 1.32 (SD ± 0.75) | 2.03 (SD ± 0.96) | P = .014 |
| Li et al, 2020100 | Mean total urokinase | 0.71 (SD ± 0.12) | 0.69 (SD ± 0.15) | P = .412 |
| Pouncey et al, 2020103 | Lysis volume used | 43.0 mg | 57.5 mg | P = .011 |
| Tian et al, 2021105 | Urokinase dose | 0.17 (SD ± 0.05) | 1.08 (SD ± 0.40) | P < .0001 |
| Xu et al, 2021107 | Urokinase dose | 95.16 (SD ± 45.89) | 293.76 (SD ±42.71) | P = .0 |
| Xu et al, 2020108 | Among those with Grade IIIb Dose of thrombolytic |
135 (SD ± 29.8) | 178.9 (SD ± 44.6) | P = .048 |
| Zhu et al, 2020109 | Urokinase amount | 0.26 (SD ± 0.14) | 1.87 (SD ± 0.53) | P = .0 |
| Vacuum Aspiration (Indigo) | ||||
| No studies met our inclusion criteria for this MT device | ||||
| Rotational (Rotarex or Cleaner) | ||||
| We did not identify any studies that reported on this outcome of interest | ||||
| Ultrasound Assisted (EKOS) | ||||
| Baker et al, 201294 | Mean total urokinase dosec | 1.7 (IQR: 1.4-2.4) | 2.1 (IQR: 1.6-2.7) | P = .10 |
| Tichelaar et al, 2016106 | Proportion of patients who had reduced thrombolytic doses compared to rtPA standard dosing | 27% (n = 9) | 21% (n = 13) | P = .49 |
Abbreviations: DVT, deep vein thrombosis; IQR, interquartile range; MT, mechanical thrombectomy; PMT, pharmacomechanical thrombectomy; SD, standard deviation.
a
The urokinase dose unit of measurement was inconsistent across the studies; however, this did not inhibit our analysis as the findings of interest are relative dose differences between study groups within any individual study.
b
Findings were similar for those with Grade II, but not significantly different among those patients with Grade I.
c
Findings were similar for rtPA and Tenecteplase use.